FDA approves apitegromab for spinal muscular atrophy; may counter Mounjaro muscle loss

The US FDA approved apitegromab, a muscle-targeting therapy for spinal muscular atrophy (SMA), which is also being studied to preserve muscle mass during GLP-1 weight loss. This marks a potential adjunct to drugs like Mounjaro, though efficacy in weight-loss patients remains unproven. The approval is a notable regulatory milestone but does not yet alter the obesity treatment landscape.